Microbiotix, Inc. is a clinical stage biopharmaceutical company focused on the discovery and development of proprietary small molecule drugs that target serious infectious diseases, including multi-drug resistant pathogens.

Microbiotix, Inc.

Year Rank
2020 1st
2019 2nd
2018 2nd
2017 1st
2016 1st
2015 1st
2014 2nd
2013 1st

As a testament to our innovation, Microbiotix has consistently been the top recipient of NIH awards amongst Massachusetts biotech/pharma companies.

The Company's lead therapeutic compound, MBX-400, is a potent and novel nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus (CMV). MBX-400 has successfully completed Phase 1 clinical testing.

Learn More